Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

laboratoires lehning - lobelia inflata + sambucus nigra d4 + yerba santa + ipeca 3ch + crataegus + stramonium + galeopsis ochroleuca + adrenalinum + belladonna + solidaginis herba + ephedra vulgaris - krople doustne, roztwór - -

Unia Europejska - polski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod chlorowodorek - multiple sclerosis, relapsing-remitting; colitis, ulcerative - leki immunosupresyjne - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Unia Europejska - polski - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Unia Europejska - polski - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

italfarmaco s.a. - riluzolum - zawiesina doustna - 5 mg/ml

Unia Europejska - polski - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - kannabidiol - lennox gastaut syndrome; epilepsies, myoclonic - przeciwpadaczkowe narzędzia, - epidyolex jest przeznaczony do stosowania jako uzupełnienie terapii napadów związanych z zespołem lennox gastaut (dniach) lub zespół Драве (ds), w połączeniu z clobazam, dla pacjentów w wieku powyżej 2 lat.

Unia Europejska - polski - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumaran dimetylu - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unia Europejska - polski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unia Europejska - polski - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne selektywne leki immunosupresyjne - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unia Europejska - polski - EMA (European Medicines Agency)

teva gmbh - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).